Vivos Therapeutics, Inc. reported its financial results for the three and nine months ended September 30, 2026, in a press release filed with the SEC on November 16, 2026. The company reported total revenue of $6.4 million for the third quarter of 2026, which represents a 24% increase compared to the second quarter of 2026. Over the first nine months of 2026, total revenue was $16.7 million, compared to $13.6 million for the same period in 2025.

The company noted a strategic shift in its business model, with product revenue decreasing to $1.8 million from $2.2 million in the prior quarter. This was attributed to a pivot away from appliance sales to dentists in the Vivos Integrated Provider (VIP) program. Conversely, service revenue increased by 1% to $4.6 million for the third quarter, and increased by 57% year-over-year to $12.1 million for the nine months ended September 30, 2026.

On the cost side, the company reported a 17% decrease in operating expenses for the third quarter of 2026, which totaled $7.2 million. This reduction was driven by a $1.4 million decrease in general and administrative expenses and lower sales and marketing expenses. As a result, the operating loss for the third quarter improved by 18% year-over-year to $3.9 million. For the nine-month period, the operating loss was $15.3 million.

At the end of the third quarter, cash and cash equivalents were $0.2 million, and total stockholders' equity was $2.4 million. The company also noted that it has eliminated an estimated $5 million or more in annual operating costs and exchanged approximately $6.1 million of senior secured debt for equity during 2026.

Subsequent to the quarter-end, Vivos completed the SOD Sciences transaction in October 2026. Following this transaction, the company regained compliance with Nasdaq’s stockholders' equity requirement. Management indicated that new clinical initiatives, including EEG testing and remote patient monitoring, are expected to contribute to revenue and margins beginning in the fourth quarter of 2026.